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Background: The clinical course of cystic ﬁbrosis (CF) lung disease varies between patients bearing identical CFTR mutations. This suggests
that additional genetic modiﬁers may contribute to the pulmonary phenotype. The highly conserved ancestral haplotype 8.1 (8.1AH), carried by
up to one quarter of Caucasians, comprises linked gene polymorphisms on chromosome 6 that play a key role in the inﬂammatory response:
LTA +252A/G; TNF −308G/A, HSP70-2 +1267A/G and RAGE −429T/C. As inﬂammation is a key component inducing CF lung damage, we
investigated whether the 8.1AH represents a lung function modiﬁer in CF.
Methods: We analyzed the lung function of 404 European CF patients from France (n=230), Germany (n=95) and UK (n=79). FEV1 differences
between 8.1AH carriers and non-carriers were calculated in each country and pooled using a random effects model.
Results: The frequency of 8.1AH carriers was similar between French (22%), German (29%) and UK (27%) patients. We found that 8.1AH carriers
had signiﬁcantly lower FEV1, adjusted for age classes and countries (Pb0.04, mean FEV1 difference −6.4% CI95% [−12.4%, −0.5%]). No dif-
ference was observed with respect to BMI Z-scores and chronic colonization with P. aeruginosa.
Conclusions: These ﬁndings support the concept that 8.1AH is an important genetic modiﬁer of lung disease in CF. To conclude, multiple linked
genes outside the CF locus might explain some of the variability in lung phenotype.
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[2,3]. However, the problem with the studies which have tried to
associate the severity of CF lung disease with modifier genes, for
example those involved in the innate or acquired immune re-
sponse, is that candidate polymorphisms have a very low preva-
lence in the community at large. Thus it either follows that CF
phenotypic variability is a mosaic of different rare modifiers or
that some highly prevalent but unknown co-inherited factors are
at work. With respect to the first idea, replicated results suggest
that single-nucleotide polymorphisms (SNPs) in transforming
growth factor B1 (TGFB1) [4–6] and mannose binding lectin 2
(MBL2) [7,8] genes might explain a small percentage of the ob-
served phenotypic variability. Here, we test the second idea that
differential co-inheritance of a latent but highly prevalent cassette
of linked genes (haplotypes) might underpin the observed vari-
ability in lung function. The term haplotype refers to the block
structure of a genetic region and haplotype differences mean
that the discrepancies may arise from differences in distribution
of more than one allele in combination with others. Some haplo-
types have a high prevalence in Europe and we wondered if one
of these could contribute to disease variability in large numbers of
CF patients.
The highly conserved ancestral haplotype 8.1 (8.1AH) is
encoded in the major histocompatibility complex (MHC) re-
gion on the short arm of chromosome 6 [9]. 8.1AH appeared
to be a good candidate because it is carried by up to one quarter
of Caucasians and comprises a cassette of linked alleles that
play key roles in the inflammatory response: LTA +252A/G
(Lymphotoxin A), TNF−308G/A (Tumor necrosis factor),
HSP70-2 +1267A/G (Heat shock protein) and RAGE−429T/C
(Receptor for Avanced Glycation Endproducts). Moreover,
8.1AH has been associated with delayed onset of lung bacterial
colonization in CF patients in a small cohort of Hungarian pa-
tients [10]. As airway inflammation is a key component induc-
ing CF lung damage, we investigated whether the 8.1AH
represents such modifier in European CF patients from France,
UK and Germany.
2. Methods
The study population consisted of a total of 404 European
CF patients (adults and children), enrolled from 6 CF centers
in France (230 children); one CF center in Germany (95 chil-
dren) and one CF center in UK (79 adults). The study was ap-
proved by the ethical committees of the Medical Review
Board of each participating CF center in France, Germany
and UK; and written informed consent was obtained for each
patient. The diagnosis of CF was made on the basis of two ab-
normal sweat chloride test results (N60 mmol/L) and/or identi-
fication of CF-causing mutations [11]. Clinical, biological and
functional data were obtained from hospital records from the
previous 2 to 5 years in France, Germany and UK. The data
were gathered by a single physician for each country, blinded
to the results of patient's haplotypes. Recorded data included
date of birth, sex, CFTR genotype, pulmonary function tests,
nutritional status and airways microbiology. Lung function
was assessed by spirometry in children N6 years during periodsof clinical stability. Respiratory microbial flora was determined
by microscopy and culture of lower respiratory tract secretions
or throat swabs realized every 3 months in all the CF centers.
Chronic airway colonization with Pseudomonas aeruginosa
(P. aeruginosa) was defined by the persistence of the pathogen
in at least three airway samples for at least 6 months. Nutrition-
al status was appreciated by the Z-score for the body mass
index (BMI).
Genotyping were performed by real time polymerase chain
reaction (PCR), using a 2700 thermocycler and the convention-
al Taqman primers and probes (Applied Biosystems, Foster
City, USA). Allelic discrimination was realized by endpoint
measurements with specific fluorescent oligonucleotides (de-
tection system software of the ABI prism 7000). We typed
4 linked polymorphisms of the 8.1AH: LTA +252A/G
(rs909253, NC_000006.11:g.31540313ANG), TNF−308G/A
(rs1800629, NC_000006.11:g.31543031GNA), HSP70-2 +
1267A/G (rs1061581, NC_000006.11:g.31784586GNA) and
RAGE−429T/C (rs1800625, NC_000006.11:g.32152442ANG).
Haplotypes were reconstructed using the EM algorithm,
using genotypes at the 4 linked polymorphisms [12]. As influ-
ence of 8.1 AH carriage on phenotype has been described
either with the whole haplotype, i.e. carriage of the 4 variants
simultaneously, or with part of its constituents, i.e. 3 out of
the 4 variants, we defined 8.1AH when at least one haplotype
included at least 3 variants among: LTA +252G, TNF−308A,
HSP70-2 +1267G and RAGE−429C [9,13]. The association
in 8.1AH carriage and age was tested using Cochran–Armitage
test for trend. BMI Z-scores were calculated using the WHO
2007 growth reference [14]. Colonization at age 18 was calcu-
lated using the Kaplan–Meier method and compared using the
log-rank test stratified on country. Forced expiratory volume in
1 second (FEV1) was standardized for age and sex by comput-
ing percent-predicted relative to reference Knudson equa-
tions [15,16]. Mean percent-predicted FEV1 differences
between 8.1AH carriers and others were calculated in each
country and age class and pooled using a random effects
model. Heterogeneity between FEV1 differences in the coun-
try/age class subgroups was tested using Cochran's Q statistic.
The same analysis was done for BMI Z-scores and CF specific
centiles Z-scores.
All analyses were made using the R software.3. Results
The clinical characteristics of the study population are listed in
Table 1. Median current age was 11.3 years for the French,
16 years for the German and 26.5 years for the UK patients.
Most of the individuals were pancreatic insufficient (93%) and
about half were female. Similar to the distribution of CFTR mu-
tations in CF European patients, 56% were homozygous for the
p.Phe508del CFTR mutation and 34% p.Phe508del compound
heterozygous. Distribution of the 8.1AH carriers was similar to
that observed in Caucasians [9] and similar across the 3 popula-
tions: 22% in the French; 29% in the German CF and 27% in
the UK patients (Chi-squared test=2.4; P=0.30). The frequency
Table 1
Clinical characteristics of the study population.
France Germany UK
Study population, n 230 95 79
Current age : median [range] 11 [6–18] 16 [6–18] 26.5 [23–54]
Sex, female / male 108/122 39/56 36/43
CFTR genotype, %
F508del homozygous 52% 62% 61%
F508del compound
heterozygous
37% 35% 24%
Other mutations 11% 3% 15%
Pancreatic insufficiency, % 92% 98% 91%
BMI Z-score : median [range] −0.49
[−3.33;3.80]
−0.63
[−4.54;1.24]
−0.37
[−2.77;3.26]
P. aeruginosa colonization at
age 18, % [95% CI]
51%
[41%–63%]
43%
[33%–57%]
82%
[74%–91%]
8.1AH carriers 22% 29% 27%
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P=0.18).
FEV1% predicted was smaller in 8.1AH carriers in each coun-
try and age class except in UK patients aged [26–30], with little
heterogeneity among age classes and countries (Cochran's Q sta-
tistic for heterogeneity, P=0.99).The random-effect pooled differ-
ence showed that 8.1AH carriers had significantly lower FEV1%
predicted overall (Pb0.04, mean FEV1 percent predicted differ-
ence, carriers vs. non carriers −6.4% CI95% [−12.4%, −0.5%],
Fig. 1).
Differences in BMI Z-scores according to 8.1 AH carriage
were not always in the same direction, fluctuating around
0 (Fig. 2); Cochran's Q statistic for heterogeneity, P=0.20).
The pooled measure did not reveal any difference in nutritional
status according to 8.1AH carriage (P=0.76). Finally, chronic
colonization with P. aeruginosa was not different according
to ancestral carriage (P=0.99).Fig. 1. Ancestral haplotype 8.1 AH carriage and FEV1 in European patients with cys
are shown as black squares with 95% confidence interval (segments). A random-effec
as the bottom diamond, centered on the mean difference and extending to the limits o
in 8.1 AH carriers (Pb0.04).4. Discussion
The key novel finding of the present study is that co-inheritance
of a widely prevalent ancestral haplotype 8.1AH is associated with
a greater lung disease severity in CF manifesting as a significantly
lower FEV1 across the 3 European populations including children
and adults. Our data also suggest that in modifier gene studies, ge-
netic associations at the haplotype level may be more informative
rather than focusing on individual SNPs [17]. Moreover, our data
are consistent with the current understanding of the roles of 8.1AH
in the inflammatory response. 8.1AH has indeed been associated
with excessive and uncontrolled inflammation in various inflam-
matory disorders [18,19]. In CF, inflammation is believed to
drive the progressive destruction of the lung and the decline in
lung function which is responsible for the major morbidity and
mortality [20]. 8.1AH comprises linked polymorphisms of major
pro-inflammatory cytokines including LTA, TNF, HSP and
RAGE. TNFα and LTA are 2 key members of the TNF superfam-
ily involved in the inflammatory response. HSP70-2 protects other
proteins against aggregation and mediates the folding of newly
translated proteins. In CF, protein misfolding is thought to contrib-
ute to disease pathogenesis [21]. RAGE is a member of the immu-
noglobulin superfamily, highly expressed in pulmonary tissues
and acts as a pro-inflammatory mediator via MAP kinases and
NFkB pathways activation which are both abnormal in CF [22–
24]. Moreover, neutrophils from CF airways have been shown
to express increased levels of RAGE [25]. The potential involve-
ment of this haplotype in CF phenotypic differences is consistent
with the early onset, excessive and persistent airway inflamma-
tion that is due partly to an imbalance between pro- and anti-
inflammatory cytokines in CF.
Critically, had we followed the classical single polymor-
phism approach, we would have found no association between
individual LTA, TNF, HSP and RAGE single SNPs and lung
function in our European cohort (data not shown) and yet wetic fibrosis. FEV1 differences were calculated in each country and age class and
ts pooled estimate of the FEV1 difference according to 8.1AH carriage is shown
f the pooled 95% confidence interval. On average, FEV1 was significantly lower
Fig. 2. Ancestral haplotype 8.1 AH carriage and Body Mass Index in European patients with cystic fibrosis. BMI Z-score differences were calculated in each age class
and country and are shown as black squares with 95% confidence interval (segments). A random-effects pooled estimate of the BMI Z-score difference according to
8.1AH carriage is shown as the bottom diamond, centered on the mean difference and extending to the limits of the 95% confidence interval. There was no difference
between 8.1 AH carriers and non carriers (P=0.76).
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−308G/A genotype has been previously explored as potential
lung disease modifier in different CF populations, but conflict-
ing results have been shown so far [5,6,26–28]. An association
between haplotypes including TNF variants with CF lung sever-
ity was first proposed by Yarden et al. [29]. They studied 3 vari-
ants in the TNF promoter (−851C/T, −308G/A, −238G/A) and
one in the LTA 1st intron (+691Gins/del) in 180 European
p.Phe508del homozygous CF children (58 from Belgium and
122 from the Czech Republic). They found no association for
TNF−308G/A or TNF−238G/A but patients heterozygous for
LTA +691Gins/Gdel were more likely to have a better lung func-
tion compared to patients homozygous for LTA +691Gins; fur-
thermore they observed a higher proportion of TNF−851C
carriers in the group of patients with an FEV1 below 70% pre-
dicted. These results led them to suggest that associations be-
tween the TNF gene and CF phenotypes could involve
haplotypes rather than single genotypes. The interpretation of sin-
gle locus associations has indeed several limitations, and there is
evidence that in a complex disease such as CF, analyses based on
haplotypes can provide additional power in detecting significant
association [4].
In CF, association between 8.1AH and lung disease has been
previously explored by Laki et al. in 72 CF patients, 39 of
which were p.Phe508del homozygote and 33 p.Phe508del
compound heterozygous [10]. They showed that 8.1AH was as-
sociated with delayed onset of respiratory colonization with
Staphylococcus aureus and P. aeruginosa, two major patho-
gens associated with lung disease severity in CF. They conclud-
ed that the excessive inflammatory response associated with the
8.1AH may influence the defense system efficiency against
some microorganisms. Another recent study also suggests a
protective effect of 8.1AH carriage in a healthy population
with severe pulmonary infection [30]. Several alterations of
the immune response have also been shown to be correlatedto AH 8.1, and even immunoglobulin (Ig) levels seem to be
influenced by this haplotype [31,32]. Interestingly, Candore et
al. have shown that 8.1AH carriers had decreased IgG2 serum
levels, which might decrease bacterial clearance and favor
chronic colonization [33]. Larger populations of CF patients
of European origin are now being assembled, that will help
study this issue further [34]. For example, it might be that an el-
evated inflammatory response is beneficial in the early stages of
childhood CF but ultimately becomes destructive as chronic in-
fection ensues in older patients.
In summary, our findings support the concept that the very
common 8.1AH that is randomly co-inherited with defects in
CFTR, appears to be an important genetic modifier of lung dis-
ease in CF in up to one quarter of patients. Interestingly, this
highly conserved ancestral haplotype contains a cassette of
linked genes that play a key role in the inflammatory response
which together could be involved in the excessive airway in-
flammation in CF.Funding sources
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